RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @OncotypeIQ: View the full #TAILORx #breastcancer trial results published in @NEJM! https://t.co/W8x5ypYfjS
View the full #TAILORx #breastcancer trial results published in @NEJM! https://t.co/W8x5ypYfjS
The #TAILORx #BreastCancer #Trial published @NEJM seeks to incorporate a molecular profiling test into clinical decision making to spare women unnecessary #treatment if #chemotherapy is not likely to be of substantial benefit. #personalized #medicine https
RT @drtanws: One day soon hopefully for #bladdercancer #biomarker for selection of adjuvant therapy https://t.co/Y5krmULmgW
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.c…
Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s https://t.co/gqiKsBdsB9
From TAILORx trial. For patients with early stage ER/PR+, HER2- breast cancer and Oncotype DX scores in the range of 11-25 "Endocrine therapy was noninferior to chemoendocrine therapy". Can safely eliminate chemo in 70% of early stage breast cancers. (http
RT @UVMcancercenter: .@UVMcancercenter member Marie Wood MD appeared on @wcax Health Watch to discuss findings from national clinical trial…
RT @ACLPS_: Exciting news from #TAILORx clinical trial that thousands of women with early-stage #BreastCancer don't need chemotherapy. Dete…
RT @TSamuelMD: Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |…
RT @LaskerFDN: A new paper in the @NEJM reports that genetic testing #breastcancer tumor samples enabled many #women to skip #chemotherapy…
RT @jcragostini: El estudio TAILORx (Trial Assigning Individualized Options for Treatment) es un estudio de tipo prospectivo, diseñado para…
RT @jcragostini: Hasta la reciente presentación y publicación del trabajo TAILORx en ASCO 2018, existía incertidumbre acerca del beneficio…
El estudio TAILORx (Trial Assigning Individualized Options for Treatment) es un estudio de tipo prospectivo, diseñado para evaluar si la quimioterapia adyuvante es beneficiosa en mujeres con puntaje de recurrencia intermedio (11-25) en el test de 21 genes
Hasta la reciente presentación y publicación del trabajo TAILORx en ASCO 2018, existía incertidumbre acerca del beneficio de la quimioterapia en pacientes con riesgo intermedio (entre 11 a 25) https://t.co/E7p6yAB1vk https://t.co/04gCpdeXBi
RT @UVMcancercenter: .@UVMcancercenter member Marie Wood MD appeared on @wcax Health Watch to discuss findings from national clinical trial…
.@UVMcancercenter member Marie Wood MD appeared on @wcax Health Watch to discuss findings from national clinical trial: for subset of women diagnosed with #breastcancer forgoing chemo may be an option @UVMMedCenter @UVMLarnerMed https://t.co/qnl2XyfBmh
RT @LaskerFDN: A new paper in the @NEJM reports that genetic testing #breastcancer tumor samples enabled many #women to skip #chemotherapy…
RT @TSamuelMD: Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |…
Fui perguntar pra uma professora o quão distante esse trabalho é da realidade do SUS. Não fiquei muito surpreso com a resposta dela https://t.co/uNuwJVDHNo
RT @NEJMGroup: Top studies published in @NEJM this week during #ASCO18: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/20…
RT @LaskerFDN: A new paper in the @NEJM reports that genetic testing #breastcancer tumor samples enabled many #women to skip #chemotherapy…
RT @TSamuelMD: Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |…
RT @TSamuelMD: Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |…
RT @TSamuelMD: Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer |…
A new paper in the @NEJM reports that genetic testing #breastcancer tumor samples enabled many #women to skip #chemotherapy and take a drug that blocks or stops #estrogen instead #TAILORx @jsparano https://t.co/z1dLaY15Uh
Many women with common breast cancer can safely skip chemo-therapy, according to a recent study. https://t.co/WriKPuHI0x https://t.co/4GO4lnLQyz
Game-changer for early stage breast cancer !! Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/YWF6IOVRox
"The 21-gene recurrence-score assay (Oncotype DX, Genomic Health) is one of several commercially available gene-expression assays that provide prognostic information in hormone-receptor–positive breast cancer.10,11 The... https://t.co/feYFKI3wcQ
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/lSod41raKQ
#GoodNews: a study led by @ae_cancercenter revealed that a 21-gene test performed on tumours will equip oncologists with essential data to enable them to offer women with early breast cancer better advice about whether to have chemotherapy. https://t.co/Hb
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
RT @jrgralow: T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https…
T1: and here's a @breastcancerorg summary of genomic testing, including onctoype dx, in early stage breast cancer #bcsm https://t.co/V3thl3NqXz
RT @DrAttai: #bcsm T1 and here's a link to the @NEJM article on TAILORx https://t.co/lQ53T3mUcD
RT @DrAttai: #bcsm T1 and here's a link to the @NEJM article on TAILORx https://t.co/lQ53T3mUcD
RT @DrAttai: #bcsm T1 and here's a link to the @NEJM article on TAILORx https://t.co/lQ53T3mUcD
SurgOnc journal club today discussing the recent TAILORx trial for breast cancer. Most are rejoicing that 60% of pts won’t need chemotherapy anymore. But isn’t the real msg➡️a $2000 dollar routinely ordered test fails to predict who needs chemo? https://t.
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @mytripleneglife: If anyone would like to read the article #BCCIre #bccww @bccire 👇🏽 https://t.co/ZvJ1WXVlXC
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Updates on oncotype dx. Finding who not to treat may have some value https://t.co/M6SUxRGwNo
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
#TAILORx study shows chemotherapy can be spared in about 70% of women with ER +ve, HER2 -ve, node -ve #BreastCancer. Women >50yrs old with Breast Recurrence Scores® of 0 - 25 and aged 50 or younger with scores of 0 to 15 https://t.co/WjRWKx6s4n
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
هاتقلِب الدنيا https://t.co/7YuLVCb6dN
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #breastcancer | NEJM https://t.co/pHpRUJW3BP https://t.co/Bio87a1FIw
RT @IlindelatorreMD: Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No dis…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @UABPathology: The power of translational research and molecular biomarkers. New Standard of care in breast cancer management. https://…
Genetic study indicates that most women with early-stage #BreastCancer benefit from surgery and hormone therapy; can skip #chemotherapy. #oncology #medicine https://t.co/NWirWpdul4
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer #hljc18 https://t.co/5YUbiXOoUj
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @mytripleneglife: If anyone would like to read the article #BCCIre #bccww @bccire 👇🏽 https://t.co/ZvJ1WXVlXC
RT @IlindelatorreMD: Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No dis…
RT @IlindelatorreMD: Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No dis…
RT @IlindelatorreMD: Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No dis…
RT @IlindelatorreMD: Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No dis…
Características de los cánceres de mama que no necesitan quimioterapia: - Aún pueden tratarse con hormonas. - No diseminación a ganglios linfáticos. - Ausencia de la mutación HER2 - Puntaje bajo en el test genético. https://t.co/VsAc9YtteQ
Exciting news from #TAILORx clinical trial that thousands of women with early-stage #BreastCancer don't need chemotherapy. Determining what patients are eligible relied on a 21-gene expression test @NEJM https://t.co/UFmocYyvWP @nytimes https://t.co/r4aDp
International study #TAILORx finds many women with early-stage #breastcancer who would receive #chemotherapy under current standards don't benefit from it. Via @NEJM @NYTHealth https://t.co/mcKlO9Jthk https://t.co/FQ3DBR33RM
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @ATGgroupNZ: This gene expression test could change the approach to the treatment of breast cancer https://t.co/70YfeJwPNm
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…